Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes-Reference-Cited by-同舟云学术

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes

Published:2024-07 Issue:7 Volume:8 Page:
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:HemaSphere

Author:

Groen Kazimierz¹²^ORCID,Smits Febe¹²,Nasserinejad Kazem³⁴,Levin Mark‐David⁵,Regelink Josien C.⁶,Timmers Gert‐Jan⁷,de Waal Esther G. M.⁸,Westerman Matthijs⁹,Velders Gerjo A.¹⁰,de Heer Koen¹¹,Leys Rineke B. L.¹²,van Kampen Roel J. W.¹³,Stege Claudia A. M.¹²⁴,Seefat Maarten R.¹²,Nijhof Inger S.¹¹⁴,van der Spek Ellen¹⁵,Klein Saskia K.⁶¹⁶,van de Donk Niels W. C. J.¹²,Ypma Paula F.¹⁷,Zweegman Sonja¹²

Affiliation:

1. Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam The Netherlands

2. Cancer Center Amsterdam, Treatment and Quality of life Amsterdam The Netherlands

3. HOVON Foundation Rotterdam The Netherlands

4. Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands

5. Department of Internal Medicine Albert Schweitzer Hospital Dordrecht The Netherlands

6. Department of Internal Medicine Meander Medical Centre Amersfoort The Netherlands

7. Department of Internal Medicine Amstelland Hospital Amstelveen The Netherlands

8. Department of Internal Medicine Medical Centre Leeuwarden Leeuwarden The Netherlands

9. Department of Internal Medicine Northwest Clinics Alkmaar The Netherlands

10. Department of Internal Medicine Gelderse Vallei Ede The Netherlands

11. Department of Internal Medicine Flevoziekenhuis Almere The Netherlands

12. Department of Internal Medicine Maasstad Hospital Rotterdam The Netherlands

13. Department of Internal Medicine Zuyderland Hospital Sittard‐Geleen The Netherlands

14. Department of Internal Medicine Antonius Ziekenhuis Nieuwegein The Netherlands

15. Department of Internal Medicine Rijnstate Hospital Arnhem The Netherlands

16. Department of Hematology University Medical Center Groningen Groningen The Netherlands

17. Department of Hematology Hagaziekenhuis, Den Haag The Netherlands

Funder

Takeda Pharmaceutical Company

Janssen Pharmaceuticals

KWF Kankerbestrijding

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hem3.85

Reference11 articles.

1. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

2. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

3. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

4. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

5. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma